Related Experiment Video
Updated: Jun 25, 2025

Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells
Published on: August 17, 2022
Therapeutic Avenues to Modulate B-Cell Function in Patients With Cardiovascular Disease
James W O'Brien1, Ayden Case1, Claudia Kemper2
1Division of Cardiorespiratory Medicine, Department of Medicine, Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, United Kingdom (J.W.O., A.C., T.X.Z., Z.M.).
Abstract:
The adaptive immune system plays an important role in the development and progression of atherosclerotic cardiovascular disease. B cells can have both proatherogenic and atheroprotective roles, making treatments aimed at modulating B cells important therapeutic targets. The innate-like B-cell response is generally considered atheroprotective, while the adaptive response is associated with mixed consequences for atherosclerosis. Additionally, interactions of B cells with components of the adaptive and innate immune system, including T cells and complement, also represent key points for therapeutic regulation. In this review, we discuss therapeutic approaches based on B-cell depletion, modulation of B-cell survival, manipulation of both the antibody-dependent and antibody-independent B-cell response, and emerging immunization techniques.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Heart Failure Drugs: β-Blockers
Cardiovascular Drugs: Classification based on Therapeutic Indications
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...

